KR870001312A - 융합 단백질의 제조방법 - Google Patents
융합 단백질의 제조방법 Download PDFInfo
- Publication number
- KR870001312A KR870001312A KR1019860006142A KR860006142A KR870001312A KR 870001312 A KR870001312 A KR 870001312A KR 1019860006142 A KR1019860006142 A KR 1019860006142A KR 860006142 A KR860006142 A KR 860006142A KR 870001312 A KR870001312 A KR 870001312A
- Authority
- KR
- South Korea
- Prior art keywords
- fusion protein
- amino acids
- sequence
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
내용 없음.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 플라스미드 pH 120/14의 제조공정.
제2도는 플라스미드 pH 106/4의 제조공정.
제3도는 플라스미드 pH 154/25의 제조공정.
제12도는 플라스미드 pInt 13의 제조공정.
Claims (12)
- 융합 단백질을 암호화하는 유전자 구조를 숙주 세포에서 발현시키고 융합 단백질을 분리하여 일반식(Ⅰ)의 융합 단백질을 제조하는 방법.Met-Xn-D'-Y-Z (1)상기식에서, n은 0 또는 1이고, X는 유전적으로 암호화할 수 있는 아미노산 1 내지 12개의 서열이며, D'은 이·콜라이 trp 오페론중 D-펩티드의 아미노산 23-93 서열부위에 있는 약 70개의 아미노산 서열이고, Y는 이어지는 아미노산 서열 Z를 절단해 낼 수 있게 하는 유전적으로 암호화할 수 있는 아미노산 한개, 또는 그 이상의 서열을 나타내며, Z는 유전적으로 암호화할 수 있는 아미노산 서열이다.
- 제1항에 있어서, n이 1이고 X가 5개까지의 아미노산을 포함하는 일반식(Ⅰ)의 융합 단백질에 대한 구조 유전자로 이루어진 방법.
- 제1 또는 2항에 있어서, n이 1이고 Lys-Ala이 X의 N-종결 말단에 위치하는 일반식(Ⅰ)의 융합 단백질에 대한 유전자 구조로 이루어진 방법.
- 제1 내지 3항중 어느 한 항에 있어서, Y가 C-종결 말단에 Met,Cys,Trp,Arg 또는 Lys 또는 m이 1,2 또는 3을 나타내는 그룹(Asp)m-Pro 또는 Glu-(Asp)m-Pro 또는 Ile-Glu-Gly-Arg 중 하나를 함유하거나, 또는 이들 아미노산으로 구성 또는 이들 그룹 중 하나로 구성되는 일반식(Ⅰ)의 융합 단백질에 대한 유전자 구조로 이루어진 방법.
- 제1 내지 4항 중 어느 한 항에 있어서, Z가 사람 프로인슐린 또는 히루딘의 아미노산 서열을 나타내는 일반식(Ⅰ)의 융합 단백질에 대한 구조 유전자로 이루어진 방법.
- 제1 내지 5항 중 어느 한 항에 있어서, DNA 서열(Ⅰ)(별첨)이 D'을 암호화하는 일반식(Ⅰ)의 융합 단백질에 대한 유전자 구조로 이루어진 방법.
- 제6항에 있어서, 하기 DNA 서열(암호화 본쇄)이 유전자 구조에서 X를 암호화하는 방법.5' AAA GCA AAG GGC 3'
- 제1 내지 7항 중 어느 한 항에 있어서, 융합 단백질이 불용성이도록 유전자 구조를 선택하는 방법.
- 제1 내지 8항 중 어느 한 항에 있어서, 유전자 구조를 이·콜라이 trp 오페론으로부터의 프로모터, 오퍼레이터 및 L-펩티드의 리보솜 결합 부위를 함유하는 벡터의 상태에 함유시키는 방법.
- 제9항에 있어서, 벡터가 위치 29 HnidⅢ 부위에서 위치 2066 PvuⅡ 부위까지의 절편이 pBR 322 DNA로 부터 결실된 pBR 322의 유도체인 방법.
- 제1 내지 10항 중 어느 한 항에 있어서, 숙주 세포가 이·콜라이인 방법.
- 제1 내지 11항에서 청구한 바와 같이 수득한 융합 단백질로부터 아미노산 서열 Z를 화학적으로 또는 효소적으로 절단하여 진핵 단백질을 제조하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19853526995 DE3526995A1 (de) | 1985-07-27 | 1985-07-27 | Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung |
DEP3526995.2 | 1985-07-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR870001312A true KR870001312A (ko) | 1987-03-13 |
KR950000299B1 KR950000299B1 (ko) | 1995-01-13 |
Family
ID=6276985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019860006142A KR950000299B1 (ko) | 1985-07-27 | 1986-07-26 | 융합 단백질의 제조방법 |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP0211299B1 (ko) |
JP (1) | JPH07113040B2 (ko) |
KR (1) | KR950000299B1 (ko) |
AT (1) | ATE50596T1 (ko) |
AU (1) | AU595221B2 (ko) |
CA (1) | CA1336329C (ko) |
DE (2) | DE3526995A1 (ko) |
DK (1) | DK172618B1 (ko) |
ES (1) | ES2000278A6 (ko) |
FI (1) | FI86887C (ko) |
GR (1) | GR861957B (ko) |
HU (1) | HU197356B (ko) |
IE (1) | IE59127B1 (ko) |
IL (1) | IL79522A (ko) |
NO (1) | NO175640C (ko) |
NZ (1) | NZ216967A (ko) |
PT (1) | PT83065B (ko) |
ZA (1) | ZA865556B (ko) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3738541A1 (de) * | 1987-11-13 | 1989-05-24 | Hoechst Ag | Verfahren zur isolierung und reinigung von hirudin |
DE3541856A1 (de) * | 1985-11-27 | 1987-06-04 | Hoechst Ag | Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens |
ATE80913T1 (de) * | 1986-03-12 | 1992-10-15 | Int Minerals & Chem Corp | Hybride expressionsvektoren, deren herstellung und verwendungen. |
WO1988010299A1 (en) * | 1987-06-24 | 1988-12-29 | Novo-Nordisk A/S | A process for preparing a protein or polypeptide, a dna sequence coding for the polypeptide, a microorganism containing the dna sequence as well as the polypeptide and its use as a pharmaceutical preparation |
US5179196A (en) * | 1989-05-04 | 1993-01-12 | Sri International | Purification of proteins employing ctap-iii fusions |
US5227293A (en) * | 1989-08-29 | 1993-07-13 | The General Hospital Corporation | Fusion proteins, their preparation and use |
GR1005153B (el) * | 1989-08-29 | 2006-03-13 | The General Hospital Corporation | Πρωτεινες συντηξεως, παρασκευη τους και χρηση τους. |
US5358857A (en) * | 1989-08-29 | 1994-10-25 | The General Hospital Corp. | Method of preparing fusion proteins |
GB8927722D0 (en) * | 1989-12-07 | 1990-02-07 | British Bio Technology | Proteins and nucleic acids |
DE3942580A1 (de) * | 1989-12-22 | 1991-06-27 | Basf Ag | Verfahren zur herstellung von hirudin |
DK0821006T3 (da) | 1996-07-26 | 2004-08-16 | Aventis Pharma Gmbh | Insulinderivater med öget zinkbinding |
DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
DE19825447A1 (de) | 1998-06-06 | 1999-12-09 | Hoechst Marion Roussel De Gmbh | Neue Insulinanaloga mit erhöhter Zinkbildung |
DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
EP2522728A1 (en) | 2007-09-21 | 2012-11-14 | Cadila Healthcare Limited | GCSF fusion protein systems suitable for high expression of peptides |
LT2349324T (lt) | 2008-10-17 | 2017-12-27 | Sanofi-Aventis Deutschland Gmbh | Insulino ir glp-1 agonisto derinys |
CN102711804B (zh) | 2009-11-13 | 2015-09-16 | 赛诺菲-安万特德国有限公司 | 包含glp-1激动剂和甲硫氨酸的药物组合物 |
CA2780460C (en) | 2009-11-13 | 2018-09-04 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine |
RU2546520C2 (ru) | 2010-08-30 | 2015-04-10 | Санофи-Авентис Дойчланд Гмбх | Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
AU2012300978B2 (en) | 2011-08-29 | 2017-04-27 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
HUE062573T2 (hu) | 2014-12-12 | 2023-11-28 | Sanofi Aventis Deutschland | Glargin inzulin/lixiszenatid rögzített arányú készítmény |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
KR20200080748A (ko) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법 |
KR20200080747A (ko) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR68404B (ko) * | 1979-06-01 | 1981-12-29 | Univ California | |
ZA811368B (en) * | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
AU596585B2 (en) * | 1985-03-18 | 1990-05-10 | Genelabs Incorporated | Hybrid genes (eg. ig's & mhc proteins) via lambda library andplasmid casette vector |
GB8507666D0 (en) * | 1985-03-25 | 1985-05-01 | Wellcome Found | Epidermal growth factor production |
CA1341384C (en) * | 1985-04-08 | 2002-08-20 | Susan Mitsue Watanabe | Expression and diagnostic use of gag encoded peptides which are immunologically reactive with antibodies to lav |
-
1985
- 1985-07-27 DE DE19853526995 patent/DE3526995A1/de not_active Withdrawn
-
1986
- 1986-07-19 AT AT86109945T patent/ATE50596T1/de active
- 1986-07-19 DE DE8686109945T patent/DE3669175D1/de not_active Expired - Lifetime
- 1986-07-19 EP EP86109945A patent/EP0211299B1/de not_active Expired - Lifetime
- 1986-07-24 ES ES8600544A patent/ES2000278A6/es not_active Expired
- 1986-07-24 FI FI863041A patent/FI86887C/fi not_active IP Right Cessation
- 1986-07-25 PT PT83065A patent/PT83065B/pt unknown
- 1986-07-25 GR GR861957A patent/GR861957B/el unknown
- 1986-07-25 DK DK198603554A patent/DK172618B1/da not_active IP Right Cessation
- 1986-07-25 CA CA000514682A patent/CA1336329C/en not_active Expired - Lifetime
- 1986-07-25 HU HU863100A patent/HU197356B/hu unknown
- 1986-07-25 NO NO863000A patent/NO175640C/no unknown
- 1986-07-25 IL IL79522A patent/IL79522A/xx not_active IP Right Cessation
- 1986-07-25 ZA ZA865556A patent/ZA865556B/xx unknown
- 1986-07-25 NZ NZ216967A patent/NZ216967A/xx unknown
- 1986-07-25 IE IE197786A patent/IE59127B1/en not_active IP Right Cessation
- 1986-07-25 AU AU60565/86A patent/AU595221B2/en not_active Expired
- 1986-07-26 JP JP61176558A patent/JPH07113040B2/ja not_active Expired - Lifetime
- 1986-07-26 KR KR1019860006142A patent/KR950000299B1/ko not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PT83065A (de) | 1986-08-01 |
FI863041A0 (fi) | 1986-07-24 |
KR950000299B1 (ko) | 1995-01-13 |
EP0211299B1 (de) | 1990-02-28 |
DK172618B1 (da) | 1999-03-01 |
NO175640B (ko) | 1994-08-01 |
GR861957B (en) | 1986-11-25 |
JPS6229600A (ja) | 1987-02-07 |
ZA865556B (en) | 1987-03-25 |
FI86887C (fi) | 1992-10-26 |
AU595221B2 (en) | 1990-03-29 |
DE3669175D1 (de) | 1990-04-05 |
ATE50596T1 (de) | 1990-03-15 |
DK355486D0 (da) | 1986-07-25 |
IL79522A0 (en) | 1986-10-31 |
NO175640C (no) | 1994-11-09 |
DE3526995A1 (de) | 1987-02-05 |
HUT43629A (en) | 1987-11-30 |
PT83065B (pt) | 1989-02-28 |
EP0211299A2 (de) | 1987-02-25 |
FI863041A (fi) | 1987-01-28 |
AU6056586A (en) | 1987-01-29 |
IE59127B1 (en) | 1994-01-12 |
NZ216967A (en) | 1988-08-30 |
IL79522A (en) | 1991-08-16 |
IE861977L (en) | 1987-01-27 |
JPH07113040B2 (ja) | 1995-12-06 |
ES2000278A6 (es) | 1988-02-01 |
FI86887B (fi) | 1992-07-15 |
DK355486A (da) | 1987-01-28 |
NO863000L (no) | 1987-01-28 |
NO863000D0 (no) | 1986-07-25 |
CA1336329C (en) | 1995-07-18 |
EP0211299A3 (en) | 1988-06-01 |
HU197356B (en) | 1989-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR870001312A (ko) | 융합 단백질의 제조방법 | |
AU644105B2 (en) | Production of biologically active insulin-like growth factor I from high expression host cell systems | |
EP0722461A4 (en) | EXPRESSION OF FUSION POLYPEPTIDES TRANSPORTED OUT OF CYTOPLASM WITHOUT HEAD SEQUENCE | |
ES2333942T3 (es) | Precursores de insulina y proceso para su preparacion. | |
AU4247485A (en) | Recombinant fusion proteins | |
NO176481B (no) | Fremgangsmåte for fremstilling av et fusjonsprotein | |
IL95495A (en) | Fusion proteins their preparation and use | |
US7105314B2 (en) | Method for making human insulin precursors | |
US5334532A (en) | PDGF-B fusion protein, vectors, and host cells for use in production thereof | |
KR880012758A (ko) | 폴리펩타이드의 유전공학적 제조방법 | |
CA2379571A1 (en) | Process for the production of a heterologous peptide by autoproteolytic cleavage in vitro | |
ES2242969T3 (es) | Vector para la expresion de proteinas con prolongacion n-terminal en celulas de levadura. | |
JP4386722B2 (ja) | アシル化されたポリペプチドの製造方法 | |
KR880014102A (ko) | 스트렙토마이세테스(Streptomycetes)에서 외래성 단백질을 제조하는 방법 | |
KR940004543B1 (ko) | 이.콜라이의 trp 발현 시스템을 갖는 벡터를 제조하는 방법 | |
WO1986001540A1 (en) | Modified insulin precursors products and processes | |
KR830007827A (ko) | 신규 재조합 플라스미드의 제조방법 | |
KR900702047A (ko) | 재조합 pdgf와 그 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20051221 Year of fee payment: 12 |
|
EXPY | Expiration of term |